BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chaudhuri KR, Odin P. The challenge of non-motor symptoms in Parkinson’s disease. Recent Advances in Parkinson’S Disease - Translational and Clinical Research. Elsevier; 2010. pp. 325-41. [DOI: 10.1016/s0079-6123(10)84017-8] [Cited by in Crossref: 106] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Sjödahl Hammarlund C, Westergren A, Åström I, Edberg AK, Hagell P. The Impact of Living with Parkinson's Disease: Balancing within a Web of Needs and Demands. Parkinsons Dis 2018;2018:4598651. [PMID: 30151098 DOI: 10.1155/2018/4598651] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
2 Kinateder T, Marinho D, Gruber D, Hatzler L, Ebersbach G, Gandor F. Sexual Dysfunctions in Parkinson’s Disease and Their Influence on Partnership—Data of the PRISM Study. Brain Sciences 2022;12:159. [DOI: 10.3390/brainsci12020159] [Reference Citation Analysis]
3 Zou J, Weng RH, Chen ZY, Wei XB, Wang R, Chen D, Xia Y, Wang Q. Position Emission Tomography/Single-Photon Emission Tomography Neuroimaging for Detection of Premotor Parkinson's Disease. CNS Neurosci Ther 2016;22:167-77. [PMID: 26776081 DOI: 10.1111/cns.12493] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
4 Borghammer P, Knudsen K, Fedorova TD, Brooks DJ. Imaging Parkinson's disease below the neck. NPJ Parkinsons Dis 2017;3:15. [PMID: 28649615 DOI: 10.1038/s41531-017-0017-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Casu MA, Mocci I, Isola R, Pisanu A, Boi L, Mulas G, Greig NH, Setzu MD, Carta AR. Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson's Disease. Front Aging Neurosci 2020;12:31. [PMID: 32116655 DOI: 10.3389/fnagi.2020.00031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bichler Z, Lim HC, Zeng L, Tan EK. Non-motor and motor features in LRRK2 transgenic mice. PLoS One 2013;8:e70249. [PMID: 23936174 DOI: 10.1371/journal.pone.0070249] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
7 Shetty K, Krishnan S, Thulaseedharan JV, Mohan M, Kishore A. Asymptomatic Hearing Impairment Frequently Occurs in Early-Onset Parkinson's Disease. J Mov Disord 2019;12:84-90. [PMID: 30944288 DOI: 10.14802/jmd.18048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
8 Favier M, Carcenac C, Savasta M, Carnicella S. [Motivation and apathy in Parkinson's disease: implication of dopaminergic D3 receptors]. Med Sci (Paris) 2017;33:822-4. [PMID: 28994369 DOI: 10.1051/medsci/20173310004] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 Vermilyea SC, Emborg ME. The role of nonhuman primate models in the development of cell-based therapies for Parkinson's disease. J Neural Transm (Vienna) 2018;125:365-84. [PMID: 28326445 DOI: 10.1007/s00702-017-1708-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
10 van Hees PJ, van der Plas AA, van Ek GF, Putter H, Den Oudsten BL, den Ouden ME, Elzevier HW. Discussing sexuality with patients with Parkinson's disease: a survey among Dutch neurologists. J Neural Transm (Vienna) 2017;124:361-8. [PMID: 27885433 DOI: 10.1007/s00702-016-1655-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Nilsson MH, Iwarsson S. Home and health in people ageing with Parkinson's disease: study protocol for a prospective longitudinal cohort survey study. BMC Neurol 2013;13:142. [PMID: 24107116 DOI: 10.1186/1471-2377-13-142] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
12 Byeon JJ, Park MH, Shin SH, Park Y, Lee BI, Choi JM, Kim N, Park SJ, Park MJ, Lim JH, Na YG, Shin YG. In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385. Molecules 2020;25:E1106. [PMID: 32131453 DOI: 10.3390/molecules25051106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, Consiglio A, Raya A, Polgreen PM, Narayanan NS, Yuan Y, Chen Z, Su W, Han Y, Zhao C, Gao L, Ji X, Welsh MJ, Liu L. Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. J Clin Invest 2019;129:4539-49. [PMID: 31524631 DOI: 10.1172/JCI129987] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 20.0] [Reference Citation Analysis]
14 Masini D, Bonito-Oliva A, Bertho M, Fisone G. Inhibition of mTORC1 Signaling Reverts Cognitive and Affective Deficits in a Mouse Model of Parkinson's Disease. Front Neurol 2018;9:208. [PMID: 29686643 DOI: 10.3389/fneur.2018.00208] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
15 Chen L, Yang J, Lü J, Cao S, Zhao Q, Yu Z. Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples. Brain Behav 2018;8:e00941. [PMID: 29670823 DOI: 10.1002/brb3.941] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
16 Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, Sahakian BJ, Robbins TW. Targeting impulsivity in Parkinson's disease using atomoxetine. Brain 2014;137:1986-97. [PMID: 24893708 DOI: 10.1093/brain/awu117] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 10.8] [Reference Citation Analysis]
17 Masilamoni GJ, Bogenpohl JW, Alagille D, Delevich K, Tamagnan G, Votaw JR, Wichmann T, Smith Y. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain 2011;134:2057-73. [PMID: 21705423 DOI: 10.1093/brain/awr137] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 6.9] [Reference Citation Analysis]
18 Andersson N, Nilsson MH, Slaug B, Oswald F, Iwarsson S. The meaning of home questionnaire revisited: Psychometric analyses among people with Parkinson's disease reveals new dimensions. PLoS One 2020;15:e0242792. [PMID: 33284817 DOI: 10.1371/journal.pone.0242792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Reichmann H. Modern treatment in Parkinson's disease, a personal approach. J Neural Transm (Vienna) 2016;123:73-80. [PMID: 26293352 DOI: 10.1007/s00702-015-1441-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
20 Reynolds GO, Otto MW, Ellis TD, Cronin-Golomb A. The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease. Mov Disord 2016;31:23-38. [PMID: 26715466 DOI: 10.1002/mds.26484] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 10.6] [Reference Citation Analysis]
21 Lennaerts-Kats H, Ebenau A, van der Steen JT, Munneke M, Bloem BR, Vissers KCP, Meinders MJ, Groot MM. "No One Can Tell Me How Parkinson's Disease Will Unfold": A Mixed Methods Case Study on Palliative Care for People with Parkinson's Disease and Their Family Caregivers. J Parkinsons Dis 2021. [PMID: 34542031 DOI: 10.3233/JPD-212742] [Reference Citation Analysis]
22 Rial D, Castro AA, Machado N, Garção P, Gonçalves FQ, Silva HB, Tomé AR, Köfalvi A, Corti O, Raisman-Vozari R, Cunha RA, Prediger RD. Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's disease. PLoS One 2014;9:e114216. [PMID: 25486126 DOI: 10.1371/journal.pone.0114216] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 8.6] [Reference Citation Analysis]
23 Zhang RJ, Li Y, Liu Q, Gao YJ, Du J, Ma J, Sun SG, Wang L. Differential Expression Profiles and Functional Prediction of Circular RNAs and Long Non-coding RNAs in the Hippocampus of Nrf2-Knockout Mice. Front Mol Neurosci 2019;12:196. [PMID: 31447646 DOI: 10.3389/fnmol.2019.00196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
24 Gustafsson JK, Södersten M, Ternström S, Schalling E. Treatment of Hypophonia in Parkinson's Disease Through Biofeedback in Daily Life Administered with A Portable Voice Accumulator. J Voice 2021:S0892-1997(21)00342-8. [PMID: 34893384 DOI: 10.1016/j.jvoice.2021.10.009] [Reference Citation Analysis]
25 Favier M, Carcenac C, Drui G, Vachez Y, Boulet S, Savasta M, Carnicella S. Implication of dorsostriatal D3 receptors in motivational processes: a potential target for neuropsychiatric symptoms in Parkinson's disease. Sci Rep 2017;7:41589. [PMID: 28134302 DOI: 10.1038/srep41589] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
26 Reichmann H. Premotor Diagnosis of Parkinson's Disease. Neurosci Bull 2017;33:526-34. [PMID: 28776303 DOI: 10.1007/s12264-017-0159-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
27 Medeiros DC, Lopes Aguiar C, Moraes MFD, Fisone G. Sleep Disorders in Rodent Models of Parkinson's Disease. Front Pharmacol 2019;10:1414. [PMID: 31827439 DOI: 10.3389/fphar.2019.01414] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
28 Lim J, Bang Y, Choi JH, Han A, Kwon MS, Liu KH, Choi HJ. LRRK2 G2019S Induces Anxiety/Depression-like Behavior before the Onset of Motor Dysfunction with 5-HT1A Receptor Upregulation in Mice. J Neurosci 2018;38:1611-21. [PMID: 29305532 DOI: 10.1523/JNEUROSCI.4051-15.2017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
29 Oliveira SR, Dionísio PA, Correia Guedes L, Gonçalves N, Coelho M, Rosa MM, Amaral JD, Ferreira JJ, Rodrigues CMP. Circulating Inflammatory miRNAs Associated with Parkinson's Disease Pathophysiology. Biomolecules 2020;10:E945. [PMID: 32585840 DOI: 10.3390/biom10060945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
30 Cozac VV, Auschra B, Chaturvedi M, Gschwandtner U, Hatz F, Meyer A, Welge-Lüssen A, Fuhr P. Among Early Appearing Non-Motor Signs of Parkinson's Disease, Alteration of Olfaction but Not Electroencephalographic Spectrum Correlates with Motor Function. Front Neurol 2017;8:545. [PMID: 29104561 DOI: 10.3389/fneur.2017.00545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Joseph TP, Jagadeesan N, Sai LY, Lin SL, Sahu S, Schachner M. Adhesion Molecule L1 Agonist Mimetics Protect Against the Pesticide Paraquat-Induced Locomotor Deficits and Biochemical Alterations in Zebrafish. Front Neurosci 2020;14:458. [PMID: 32547358 DOI: 10.3389/fnins.2020.00458] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
32 Brundin P, Melki R. Prying into the Prion Hypothesis for Parkinson's Disease. J Neurosci 2017;37:9808-18. [PMID: 29021298 DOI: 10.1523/JNEUROSCI.1788-16.2017] [Cited by in Crossref: 132] [Cited by in F6Publishing: 82] [Article Influence: 26.4] [Reference Citation Analysis]
33 Chen K, Yang YJ, Liu FT, Li DK, Bu LL, Yang K, Wang Y, Shen B, Guan RY, Song J, Wang J, Wu JJ. Evaluation of PDQ-8 and its relationship with PDQ-39 in China: a three-year longitudinal study. Health Qual Life Outcomes 2017;15:170. [PMID: 28838316 DOI: 10.1186/s12955-017-0742-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
34 Sjödahl Hammarlund C, Nilsson MH, Idvall M, Rosas SR, Hagell P. Conceptualizing and prioritizing clinical trial outcomes from the perspectives of people with Parkinson's disease versus health care professionals: a concept mapping study. Qual Life Res 2014;23:1687-700. [PMID: 24390766 DOI: 10.1007/s11136-013-0614-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
35 Anderegg A, Poulin JF, Awatramani R. Molecular heterogeneity of midbrain dopaminergic neurons--Moving toward single cell resolution. FEBS Lett 2015;589:3714-26. [PMID: 26505674 DOI: 10.1016/j.febslet.2015.10.022] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
36 Eskow Jaunarajs KL, George JA, Bishop C. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease. Neuroscience 2012;218:243-56. [PMID: 22659568 DOI: 10.1016/j.neuroscience.2012.05.052] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
37 Rosqvist K, Hagell P, Odin P, Ekström H, Iwarsson S, Nilsson MH. Factors associated with life satisfaction in Parkinson's disease. Acta Neurol Scand 2017;136:64-71. [PMID: 27726132 DOI: 10.1111/ane.12695] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
38 Singh A, Cole RC, Espinoza AI, Evans A, Cao S, Cavanagh JF, Narayanan NS. Timing variability and midfrontal ~4 Hz rhythms correlate with cognition in Parkinson's disease. NPJ Parkinsons Dis 2021;7:14. [PMID: 33589640 DOI: 10.1038/s41531-021-00158-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
39 Hulme K, Safari R, Thomas S, Mercer T, White C, Van der Linden M, Moss-Morris R. Fatigue interventions in long term, physical health conditions: A scoping review of systematic reviews. PLoS One 2018;13:e0203367. [PMID: 30312325 DOI: 10.1371/journal.pone.0203367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
40 Koh SB, Kim JW, Ma HI, Ahn TB, Cho JW, Lee PH, Chung SJ, Kim JS, Kwon DY, Baik JS. Validation of the korean-version of the nonmotor symptoms scale for Parkinson's disease. J Clin Neurol 2012;8:276-83. [PMID: 23323136 DOI: 10.3988/jcn.2012.8.4.276] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
41 Toloraia K, Meyer A, Beltrani S, Fuhr P, Lieb R, Gschwandtner U. Anxiety, Depression, and Apathy as Predictors of Cognitive Decline in Patients With Parkinson's Disease-A Three-Year Follow-Up Study. Front Neurol 2022;13:792830. [PMID: 35211081 DOI: 10.3389/fneur.2022.792830] [Reference Citation Analysis]
42 Delaville C, Deurwaerdère PD, Benazzouz A. Noradrenaline and Parkinson's disease. Front Syst Neurosci 2011;5:31. [PMID: 21647359 DOI: 10.3389/fnsys.2011.00031] [Cited by in Crossref: 130] [Cited by in F6Publishing: 122] [Article Influence: 11.8] [Reference Citation Analysis]
43 Willison LD, Kudo T, Loh DH, Kuljis D, Colwell CS. Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model. Exp Neurol 2013;243:57-66. [PMID: 23353924 DOI: 10.1016/j.expneurol.2013.01.014] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
44 Bouwmans AE, Weber WE. Neurologists' diagnostic accuracy of depression and cognitive problems in patients with parkinsonism. BMC Neurol 2012;12:37. [PMID: 22702891 DOI: 10.1186/1471-2377-12-37] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
45 French IT, Muthusamy KA. A Review of Sleep and Its Disorders in Patients with Parkinson's Disease in Relation to Various Brain Structures. Front Aging Neurosci 2016;8:114. [PMID: 27242523 DOI: 10.3389/fnagi.2016.00114] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
46 Vermilyea SC, Emborg ME. α-Synuclein and nonhuman primate models of Parkinson's disease. J Neurosci Methods 2015;255:38-51. [PMID: 26247888 DOI: 10.1016/j.jneumeth.2015.07.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
47 Grigoriou S, Martínez-Martín P, Ray Chaudhuri K, Rukavina K, Leta V, Hausbrand D, Falkenburger B, Odin P, Reichmann H. Effects of safinamide on pain in patients with fluctuating Parkinson's disease. Brain Behav 2021;11:e2336. [PMID: 34478245 DOI: 10.1002/brb3.2336] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR. A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics 2012;9:297-314. [PMID: 22350713 DOI: 10.1007/s13311-012-0104-2] [Cited by in Crossref: 155] [Cited by in F6Publishing: 157] [Article Influence: 17.2] [Reference Citation Analysis]
49 Masini D, Lopes-Aguiar C, Bonito-Oliva A, Papadia D, Andersson R, Fisahn A, Fisone G. The histamine H3 receptor antagonist thioperamide rescues circadian rhythm and memory function in experimental parkinsonism. Transl Psychiatry 2017;7:e1088. [PMID: 28398338 DOI: 10.1038/tp.2017.58] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
50 Lee BD, Dawson VL, Dawson TM. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends Pharmacol Sci 2012;33:365-73. [PMID: 22578536 DOI: 10.1016/j.tips.2012.04.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 5.9] [Reference Citation Analysis]
51 Nuzziello N, Ciaccia L, Liguori M. Precision Medicine in Neurodegenerative Diseases: Some Promising Tips Coming from the microRNAs' World. Cells 2019;9:E75. [PMID: 31892254 DOI: 10.3390/cells9010075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
52 Adeosun SO, Hou X, Zheng B, Melrose HL, Mosley T, Wang JM. Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice. Neurobiol Learn Mem 2017;142:182-9. [PMID: 28487191 DOI: 10.1016/j.nlm.2017.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
53 Saadi H, Shan Y, Marazziti D, Wray S. GPR37 Signaling Modulates Migration of Olfactory Ensheathing Cells and Gonadotropin Releasing Hormone Cells in Mice. Front Cell Neurosci 2019;13:200. [PMID: 31143101 DOI: 10.3389/fncel.2019.00200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
54 Menegas W, Bergan JF, Ogawa SK, Isogai Y, Umadevi Venkataraju K, Osten P, Uchida N, Watabe-Uchida M. Dopamine neurons projecting to the posterior striatum form an anatomically distinct subclass.Elife. 2015;4:e10032. [PMID: 26322384 DOI: 10.7554/eLife.10032] [Cited by in Crossref: 145] [Cited by in F6Publishing: 105] [Article Influence: 20.7] [Reference Citation Analysis]
55 Keus SH, Oude Nijhuis LB, Nijkrake MJ, Bloem BR, Munneke M. Improving community healthcare for patients with Parkinson's disease: the dutch model. Parkinsons Dis 2012;2012:543426. [PMID: 22496990 DOI: 10.1155/2012/543426] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
56 Lhost J, More S, Watabe I, Louber D, Ouagazzal AM, Liberge M, Amalric M. Interplay Between Inhibitory Control and Behavioural Flexibility: Impact of Dorsomedial Striatal Dopamine Denervation in Mice. Neuroscience 2021;477:25-39. [PMID: 34634423 DOI: 10.1016/j.neuroscience.2021.09.026] [Reference Citation Analysis]
57 Haaxma CA, Borm GF, van der Linden D, Kappelle AC, Bloem BR. Artistic occupations are associated with a reduced risk of Parkinson's disease. J Neurol 2015;262:2171-6. [PMID: 26138540 DOI: 10.1007/s00415-015-7828-y] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
58 Mikkilineni S, Cantuti-Castelvetri I, Cahill CM, Balliedier A, Greig NH, Rogers JT. The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression. Parkinsons Dis 2012;2012:142372. [PMID: 22693681 DOI: 10.1155/2012/142372] [Cited by in Crossref: 6] [Cited by in F6Publishing: 23] [Article Influence: 0.6] [Reference Citation Analysis]